Literature DB >> 9488504

Antipsychotic drug regulation of AMPA receptor affinity states and GluR1, GluR2 splice variant expression.

L McCoy1, C Cox, E K Richfield.   

Abstract

We recently reported that chronic administration of antipsychotic drugs dramatically elevated [3H]AMPA binding, with minimal elevation of [3H]CNQX binding in rat brain. The aim of the current study was to examine the mechanism of this effect. Chronic haloperidol minimally increased the total number of binding sites (total Bmax) compared to saline-injected animals. Specifically, haloperidol dramatically increased the proportion of high-affinity-site AMPA receptors (approximately 30% increase) without inducing a significant change in the low-affinity constant. In situ hybridization for flip and flop isoforms of GluR1 and GluR2 (AMPA receptors) was not altered in a pattern or degree that compared to the changes seen in AMPA receptor binding. These findings suggest that the long-term action of antipsychotic drugs may be to regulate AMPA receptor responsiveness to agonist stimulation via posttranscriptional means, and is unlikely to be related to GluR1 or GluR2 splice variant expression. This effect may have relevance to both the therapeutic effects and side effects of antipsychotic drugs in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9488504     DOI: 10.1002/(SICI)1098-2396(199803)28:3<195::AID-SYN2>3.0.CO;2-5

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  9 in total

Review 1.  [Effect of antipsychotics on glutaminergic neural transmission in the animal model].

Authors:  A Schmitt; B May; B Müller; M Zink; D F Braus; F A Henn
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

Review 2.  Modulation of ligand-gated ion channels by antidepressants and antipsychotics.

Authors:  Gerhard Rammes; Rainer Rupprecht
Journal:  Mol Neurobiol       Date:  2007-04       Impact factor: 5.590

3.  AMPA receptor subunit and splice variant expression in the DLPFC of schizophrenic subjects and rhesus monkeys chronically administered antipsychotic drugs.

Authors:  J A O'Connor; E C Muly; S E Arnold; S E Hemby
Journal:  Schizophr Res       Date:  2006-12-01       Impact factor: 4.939

Review 4.  Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders.

Authors:  G J Lees
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

5.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

6.  Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia.

Authors:  Yong Kee Choi; Shikha Snigdha; Mohammed Shahid; Jo C Neill; Frank I Tarazi
Journal:  J Mol Neurosci       Date:  2009-05-20       Impact factor: 3.444

7.  Targeted disruption of Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective hematopoiesis.

Authors:  Deborah J Stumpo; Hal E Broxmeyer; Toni Ward; Scott Cooper; Giao Hangoc; Yang Jo Chung; William C Shelley; Eric K Richfield; Manas K Ray; Mervin C Yoder; Peter D Aplan; Perry J Blackshear
Journal:  Blood       Date:  2009-07-24       Impact factor: 22.113

8.  Effects of risperidone on glutamate receptor subtypes in developing rat brain.

Authors:  Yong Kee Choi; Matthew P Gardner; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2008-10-09       Impact factor: 4.600

9.  Long-term effects of JL 13, a potential atypical antipsychotic, on ionotropic glutamate receptors.

Authors:  Frank I Tarazi; Taylor Moran-Gates; Matthew P Gardner; Amaury Graulich; Cédric Lamy; Jean-François Liégeois
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.